Bone Mineral Density Testing Disparities Among Patients With Breast Cancer Prescribed Aromatase Inhibitors

Restricted access

Objectives: Aromatase inhibitors (AIs) are standard adjuvant therapy for postmenopausal women with early-stage, estrogen receptor–positive breast cancer. We designed our study to determine whether women initiating adjuvant therapy with an AI underwent baseline bone mineral density testing, as well as what factors predicted adherence with testing guidelines. Methods: Medicare Parts A, B, and D claims were used to identify a cohort of women aged 67 years and older with incident breast cancer in 2006 and 2007 who started AI therapy. Medicare claims provided information about bone density testing, as well as demographic and other treatment data through 2012. We also ascertained which patients were treated with bisphosphonates and studied the relationship of bisphosphonate therapy with bone density testing. Results: Approximately two-thirds of patients had baseline bone density testing. Older age, comorbidity, low income, and black race were associated with lower rates of baseline bone density testing. Testing rates decreased substantially with increasing age from 73% for women aged 67 to 70 years to 51% for those 85 years of age and older (adjusted odds ratio for not being tested, 2.48 [Cl, 2.17–2.82]). The proportion of women who had neither bone density testing nor bisphosphonate therapy increased with age as well. Conclusions: Despite the importance of age as a risk factor for fractures, older women starting treatment with AIs for treatment of breast cancer are less likely to undergo recommended bone density assessment.

Correspondence: John Charlson, MD, Hematology-Oncology Division, Department of Medicine, 9200 Wisconsin Avenue, Medical College of Wisconsin, Milwaukee, WI 53226. E-mail: jcharlso@mcw.eduAuthor Contributions: Study concepts: Neuner and Charlson. Study design: Neuner, Charlson, and Laud. Data acquisition: Neuner. Quality control of data and algorithms: Laud and Smith. Data analysis and interpretation: Neuner, Laud, Smith, Charlson, and Smallwood. Statistical analysis: Laud and Smith. Manuscript preparation: Neuner, Charlson, Smallwood, Laud, and Smith. Manuscript editing: Neuner, Charlson, and Smallwood. Manuscript review: Neuner, Charlson, Smallwood, Laud, and Smith.
  • 1.

    YenTWCzypinskiLKSparapaniRA. Socioeconomic factors associated with adjuvant hormone therapy use in older breast cancer survivors. Cancer2011;117:398405.

    • Search Google Scholar
    • Export Citation
  • 2.

    AmirESerugaBNiraulaS. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst2011;103:12991309.

    • Search Google Scholar
    • Export Citation
  • 3.

    NeunerJMYenTWSparapaniRA. Fracture risk and adjuvant hormonal therapy among a population-based cohort of older female breast cancer patients. Osteoporos Int2011;22:28472855.

    • Search Google Scholar
    • Export Citation
  • 4.

    LonningPEGeislerJKragLE. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol2005;23:51265137.

    • Search Google Scholar
    • Export Citation
  • 5.

    GralowJRBiermannJSFarookiA. NCCN Task Force Report: Bone Health In Cancer Care. J Natl Compr Canc Netw2013;11(Suppl 3):S150.

  • 6.

    HillnerBEIngleJNChlebowskiRT. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol2003;21:40424057.

    • Search Google Scholar
    • Export Citation
  • 7.

    LimLSHoeksemaLJSherinK. Screening for osteoporosis in the adult U.S. population: ACPM position statement on preventive practice. Am J Prev Med2009;36:366375.

    • Search Google Scholar
    • Export Citation
  • 8.

    NelsonHDHaneyEMDanaT. Screening for osteoporosis: an update for the U.S. Preventive Services Task Force. Ann Intern Med2010;153:99111.

    • Search Google Scholar
    • Export Citation
  • 9.

    EarleCCBursteinHJWinerEP. Quality of non–breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol2003;21:14471451.

    • Search Google Scholar
    • Export Citation
  • 10.

    SnyderCFFrickKDKantsiperME. Prevention, screening, and surveillance care for breast cancer survivors compared with controls: changes from 1998 to 2002. J Clin Oncol2009;27:10541061.

    • Search Google Scholar
    • Export Citation
  • 11.

    LigibelJO'MalleyAJFisherM. Patterns of bone density evaluation in a community population treated with aromatase inhibitors. Breast Cancer Res Treat2012;134:13051313.

    • Search Google Scholar
    • Export Citation
  • 12.

    SpanglerLYuOLoggersE. Bone mineral density screening among women with a history of breast cancer treated with aromatase inhibitors. J Women's Health2013;22:132140.

    • Search Google Scholar
    • Export Citation
  • 13.

    Early Breast Cancer Trialists' Collaborative Group: aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet2015;386:13411352.

    • Search Google Scholar
    • Export Citation
  • 14.

    NattingerABLaudPWBajorunaiteR. An algorithm for the use of Medicare claims data to identify women with incident breast cancer. Health Serv Res2004;39(6 Pt 1):17331749.

    • Search Google Scholar
    • Export Citation
  • 15.

    KlabundeCNLeglerJMWarrenJL. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol2007;17:584590.

    • Search Google Scholar
    • Export Citation
  • 16.

    HowellACuzickJBaumM. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet2005;365:6062.

    • Search Google Scholar
    • Export Citation
  • 17.

    van de VeldeCJReaDSeynaeveC. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet2011;377:321331.

    • Search Google Scholar
    • Export Citation
  • 18.

    Dhesy-ThindSK. Screening for osteoporosis in postmenopausal women with breast cancer receiving aromatase inhibitors: less is more?J Clin Oncol2012;30:14081410.

    • Search Google Scholar
    • Export Citation
  • 19.

    JacobsenSJGoldbergJMilesTP. Hip fracture incidence among the old and very old: a population-based study of 745,435 cases. Am J Public Health1990;80:871873.

    • Search Google Scholar
    • Export Citation
  • 20.

    HuiSLSlemendaCWJohnstonCC. Age and bone mass as predictors of fracture in a prospective study. J Clin Invest1988;81:18041809.

  • 21.

    BanksEReevesGKBeralV. Hip fracture incidence in relation to age, menopausal status, and age at menopause: prospective analysis. PLOS Med2009;6:e1000181.

    • Search Google Scholar
    • Export Citation
  • 22.

    NeunerJMBinkleyNSparapaniRA. Bone density testing in older women and its association with patient age. J Am Geriatr Soc2006;54:485489.

    • Search Google Scholar
    • Export Citation
  • 23.

    CurtisJRCarboneLChengH. Longitudinal trends in use of bone mass measurement among older americans, 1999-2005. J Bone Miner Res2008;23:10611067.

    • Search Google Scholar
    • Export Citation
  • 24.

    AftRNaughtonMTrinkausK. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol2010;11:421428.

    • Search Google Scholar
    • Export Citation
  • 25.

    GnantMMlineritschBStoegerH. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol2011;12:631641.

    • Search Google Scholar
    • Export Citation
  • 26.

    EidtmannHde BoerRBundredN. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol2010;21:21882194.

    • Search Google Scholar
    • Export Citation
  • 27.

    PerssonIAdamiHOMcLaughlinJK. Reduced risk of breast and endometrial cancer among women with hip fractures (Sweden). Cancer Causes Control1994;5:523528.

    • Search Google Scholar
    • Export Citation
  • 28.

    NewcombPATrentham-DietzAEganKM. Fracture history and risk of breast and endometrial cancer. Am J Epidemiol2001;153:10711078.

  • 29.

    GanryOPengJDubreuilA. Is there a reduced risk of breast cancer among women with hip fractures?Eur J Epidemiol1999;15:313315.

  • 30.

    ChenZMaricicMAragakiA. Fracture risk increases after diagnosis of breast or other cancers in postmenopausal women: results from the Women's Health Initiative. Osteoporos Int2009;20:527536.

    • Search Google Scholar
    • Export Citation
  • 31.

    ItoKBlinderVSElkinEB. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer. J Clin Oncol2012;30:14681475.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 148 148 9
PDF Downloads 17 17 0
EPUB Downloads 0 0 0